Foundation Fighting Blindness fund sells $2.76 million of Opus Genetics shares

IRD•2026-10-02

The Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 Opus Genetics shares for a reported $2,756,020.80 on Sept. 30, 2026, reducing its stake to 3,236,171 shares.

1. Share sale

The fund sold 556,000 Opus Genetics common shares on Sept. 30, 2026, at a weighted-average price of $4.9568 per share. Its stake fell to 3,236,171 shares after the transaction.

Sources

Foundation Fighting Blindness fund sells $2.76 million of Opus Genetics shares

Sec

Foundation Fighting Blindness fund sells $2.76 million of Opus Genetics shares

1. Share sale

Related News

First Solar CTO Markus Gloeckler disposes of $139,200 in common shares

Auburn National director William F. Ham Jr. acquires $1,287.27 in common shares

Trading halted for Nasdaq information request at 7:50 p.m.

Sources

Foundation Fighting Blindness fund sells $2.76 million of Opus Genetics shares

US FDA extends review of Novo Nordisk's hemophilia drug over facility issues

Mercer Rosenthal halts pulp mill restart and suspends Saale River wastewater discharge during discoloration probe